Investment Planning Advisors Inc. Makes New Investment in Danaher Corporation $DHR

Investment Planning Advisors Inc. bought a new stake in Danaher Corporation (NYSE:DHR) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 11,465 shares of the conglomerate’s stock, valued at approximately $2,540,000. Danaher accounts for 0.6% of Investment Planning Advisors Inc.’s holdings, making the stock its 21st largest position.

A number of other institutional investors have also bought and sold shares of DHR. BlackRock Inc. acquired a new position in shares of Danaher in the 2nd quarter valued at about $10,492,520,000. Wellington Management Group LLP grew its holdings in Danaher by 10.4% in the second quarter. Wellington Management Group LLP now owns 16,316,834 shares of the conglomerate’s stock worth $3,108,031,000 after purchasing an additional 1,542,310 shares during the period. Jupiter Topco LLC acquired a new stake in Danaher in the second quarter worth $1,456,317,000. Generation Investment Management LLP acquired a new stake in Danaher in the second quarter worth $1,287,949,000. Finally, Bank of America Corp DE bought a new stake in Danaher in the second quarter valued at $993,846,000. Institutional investors own 79.05% of the company’s stock.

Danaher Price Performance

Shares of DHR traded up $1.60 during midday trading on Wednesday, hitting $224.44. 1,963,388 shares of the company traded hands, compared to its average volume of 4,448,790. The stock has a 50-day moving average of $212.41 and a 200-day moving average of $195.13. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. Danaher Corporation has a one year low of $160.93 and a one year high of $242.80. The firm has a market cap of $157.78 billion, a P/E ratio of 39.86, a PEG ratio of 2.78 and a beta of 0.76.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. The company had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. Danaher’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.77 earnings per share. As a group, sell-side analysts predict that Danaher Corporation will post 8.53 EPS for the current fiscal year.

Danaher Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Shareholders of record on Wednesday, September 30th will be issued a $0.40 dividend. This represents a $1.60 annualized dividend and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher’s dividend payout ratio (DPR) is presently 28.42%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently weighed in on DHR shares. Barclays upped their price objective on shares of Danaher from $230.00 to $255.00 and gave the company an “overweight” rating in a report on Wednesday, October 7th. Weiss Ratings raised shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research report on Wednesday, September 16th. Guggenheim raised their price objective on Danaher from $200.00 to $250.00 and gave the company a “buy” rating in a research note on Thursday, October 1st. UBS Group started coverage on shares of Danaher in a research note on Wednesday, September 9th. They issued a “buy” rating and a $250.00 price objective for the company. Finally, Wells Fargo & Company cut their price target on shares of Danaher from $212.00 to $195.00 and set an “equal weight” rating on the stock in a report on Wednesday, July 22nd. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $235.41.

Danaher News Roundup

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: Potential earnings beat: Zacks says Danaher has a favorable combination of earnings-estimate revisions and its Earnings ESP, suggesting the company could exceed consensus expectations in its upcoming report. This is supporting optimism ahead of results. Danaher Earnings Expected to Grow
• Positive Sentiment: NVIDIA AI partnership: Danaher announced a collaboration with NVIDIA to combine its scientific instruments, automation systems, laboratory workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative could improve laboratory productivity and strengthen Danaher’s long-term growth prospects. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Autonomous-lab opportunity: Danaher plans to launch its first AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027. Although the initial market reaction was limited, the move gives investors another potential growth avenue in life-science automation and AI-driven drug discovery. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support and board changes: Morgan Stanley maintained its $240 price target, while Danaher expanded its board to 13 members with the appointments of Daniel Comas and Robert Hershberg. These developments provide stability but are not expected to materially change near-term earnings. Morgan Stanley Maintains Danaher Price Target
• Neutral Sentiment: Upcoming earnings focus: Investors are monitoring the company’s projected earnings announcement, with expectations for earnings growth likely to keep attention on execution and forward guidance. Danaher Projected Earnings Announcement

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.